A team of researchers led by NYU Tandon School of Engineering’s Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.

The team’s microscope slide-sized “leukemia-on-a-chip” is the first laboratory device to successfully combine both the physical structure of bone marrow and a functioning human immune system, an advance that could dramatically accelerate new immunotherapy development.

This innovation comes at a particularly timely moment, as the FDA recently announced a plan to phase out animal testing requirements for monoclonal antibodies and other drugs, releasing a comprehensive roadmap for reducing animal testing in preclinical safety studies.